{
  "report_rows": [
    {
      "kpi": "Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$2.57 vs. cons $2.53",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$1.52B vs. cons $1.51B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "AST constant-currency organic revenue growth",
      "prediction": "MISS",
      "answer": "pred ~4.0% vs. cons 5.0%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY27 adjusted EPS",
      "prediction": "UNCHANGED",
      "answer": "guide ~$11.20 vs. cons $11.23 (FY27)",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY27 constant-currency organic revenue growth",
      "prediction": "UNCHANGED",
      "answer": "guide ~6.5% vs. cons 6.3% (FY27)",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY27 AST constant-currency organic revenue growth",
      "prediction": "UNCHANGED",
      "answer": "guide ~7.5% vs. cons 7.4% (FY27)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": -2.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -3.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "An EPS beat of ~$2.57 versus $2.53 is likely outweighed by AST organic growth of ~4.0% versus 5.0%, reinforcing the slower-first-half narrative. Retaining FY27 EPS guidance at ~$11.20 versus $11.23 preserves the formal outlook, but it leaves more of the annual AST recovery and margin delivery weighted to the second half; out-period estimates can drift lower by roughly 1.5% versus current FY27 math despite an in-line consolidated revenue result of ~$1.52B versus $1.51B.",
  "day5_confidence": "MEDIUM"
}